Fortress Biotech (FBIO)
(Delayed Data from NSDQ)
$1.80 USD
+0.02 (1.12%)
Updated Jun 7, 2024 03:59 PM ET
After-Market: $1.80 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Fortress Biotech, Inc. [FBIO]
Reports for Purchase
Showing records 261 - 280 ( 315 total )
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Results; Thesis Stays Strong as Multiple Assets Make Significant Progress towards Approval
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Plenty of News Flow - Avenue - Mustang
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Building Model T''s- A Biotech Machine
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 Recap - Derm Business Tops Targets; Catalysts Ahead
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 Results; Building a Fortress of Catalysts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
We launch coverage of Fortress Biotech, Inc. with a Buy rating and a $4/ share price target.
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
1Q19 Results; Follow the Numbers as Portfolio Opportunities and Catalysts Grow
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J